Maternal risk appropriate care has been proposed by the American College of Obstetricians & Gynecologists (ACOG), Society of Maternal Fetal Medicine (SMFM), the Centers for Disease Control (CDC) and other stakeholders as a national system-wide recommendation to improve safety in childbirth and to decrease the rising rate of maternal morbidity and mortality. ACOG, SMFM, and various other stakeholders have advocated for certifying hospitals based on hospital resources with a system ranked from I-IV where Level I has essential resources and provides care for low risk women, Level II and III takes care of intermediate risk women, and Level IV is a regional center with 24/7 access to onsite multidisciplinary consultants and critical care resources. In response to the NIH IMPROVE initiative, this supplement proposal focuses on hemorrhage--the 4th leading cause of maternal mortality. Reports suggest that upwards of 66-93% may be avoidable making it the leading cause of preventable maternal death. Abnormal placentation (placenta accreta spectrum (PAS) disorders and placenta previa) is a leading cause of hemorrhage. Rates are increasing due to increasing rates of cesarean delivery, and risk of cesarean varies by race/ethnicity. Many researchers, clinicians, and patient advocacy groups support regionalizing care for women with PAS with care coordinated by centers of excellence or accreta centers? with designated teams and standardized protocols. However, to date, there has not been a systematic evaluation of outcomes by hospitals based on risk appropriate care at the hospital level, and even the specialized ?accreta centers? have not provided data demonstrating improvement in health disparities. In response to the NIH IMPROVE initiative, the current proposal uses California discharge data (2013-2016), to address the following study aims: (1) describe maternal outcomes in women with abnormal placentation (PAS or placenta previa) by level of maternal care and race/ethnicity; (2) evaluate the interactions of levels of maternal care and race/ethnicity on severe maternal morbidity (SMM) for women with PAS; and (3) evaluate the interaction of levels of maternal care and race/ethnicity on SMM for women with placenta previa?an alternate condition that likely could be influenced by maternal risk appropriate care. This study will be the first to evaluate if outcomes are better for women with PAS or placenta previa based on risk appropriate care and if level of care mitigates observed disparities in SMM for these high-risk conditions. Further, this study provides a framework to study different clinical conditions where referral to risk appropriate care can be evaluated.

Public Health Relevance

Maternal risk appropriate care has been proposed as a national system-wide recommendation to improve safety in childbirth and to decrease the rising rate of maternal morbidity and mortality. The current proposal uses California discharge data (2013-2016) to describe maternal outcomes in women with abnormal placentation?placenta accreta syndrome (PAS) and placenta previa by level of maternal care and race/ethnicity, and evaluates the interactions of levels of maternal care and race/ethnicity on severe maternal morbidity (SMM) for women with PAS and placenta previa. This study will be the first to evaluate if outcomes are better for women with PAS or placenta previa based on risk appropriate care and if level of care mitigates observed disparities in SMM for these high-risk conditions.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR001881-05S1
Application #
10200543
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Chang, Soju
Project Start
2016-07-01
Project End
2021-05-31
Budget Start
2020-09-18
Budget End
2021-05-31
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Norris, Keith C; Nicholas, Susanne B (2018) Community-Based CKD Screening in Black Americans. Clin J Am Soc Nephrol 13:521-523
Li, Michael J; Kechter, Afton; Olmstead, Richard E et al. (2018) Sleep and mood in older adults: coinciding changes in insomnia and depression symptoms. Int Psychogeriatr 30:431-435
Hui, Simon T; Kurt, Zeyneb; Tuominen, Iina et al. (2018) The Genetic Architecture of Diet-Induced Hepatic Fibrosis in Mice. Hepatology 68:2182-2196
Menees, Stacy B; Almario, Christopher V; Spiegel, Brennan M R et al. (2018) Prevalence of and Factors Associated With Fecal Incontinence: Results From a Population-Based Survey. Gastroenterology 154:1672-1681.e3
Laetsch, Theodore W; DuBois, Steven G; Mascarenhas, Leo et al. (2018) Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19:705-714
Schaenman, J M; Rossetti, M; Sidwell, T et al. (2018) Increased T cell immunosenescence and accelerated maturation phenotypes in older kidney transplant recipients. Hum Immunol 79:659-667
Mahajan, Anubha (see original citation for additional authors) (2018) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet 50:559-571
Hu, Junhui; Schokrpur, Shiruyeh; Archang, Maani et al. (2018) A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. Mol Ther Methods Clin Dev 9:203-210
Brown, Arleen F; Liang, Li-Jung; Vassar, Stefanie D et al. (2018) Trends in Racial/Ethnic and Nativity Disparities in Cardiovascular Health Among Adults Without Prevalent Cardiovascular Disease in the United States, 1988 to 2014. Ann Intern Med 168:541-549
Jiang, Jiansen; Wang, Yaqiang; SuĊĦac, Lukas et al. (2018) Structure of Telomerase with Telomeric DNA. Cell 173:1179-1190.e13

Showing the most recent 10 out of 287 publications